Breaking News

Novartis Selects PharmaVentures for Horsham Site Options

April 14, 2014

Will look to reuse part of the site as a science or business park

Novartis has selected PharmaVentures as advisors to address options for its UK Horsham site. In February, Novartis announced plans to close the Horsham site following a global review of its research operations.
Options for the site could include reusing part of the site as a science or business park. PharmaVentures will provide advice on this possibility and will help identify potential partners.
Dr. Fintan Walton, chief executive officer of PharmaVentures, said, "The Novartis Horsham site is a perfect location for a high technology park. Novartis has built state of the art facilities, suitable for pharmaceutical / life science or other high technology businesses. With such high quality facilities, we expect interest from both universities and research institutes. The site would also be ideal as a business park as Horsham is an attractive location due to its strong international links through Gatwick airport and its proximity to London."
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision